晚期非小细胞肺癌吉非替尼二线和三线治疗的疗效比较

目的:探讨吉非替尼用于晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)二线或三线治疗对患者生存期的影响。方法:回顾性分析106例晚期NSCLC患者的病历和随访资料,其中62例患者接受吉非替尼二线治疗,44例患者接受吉非替尼三线治疗。应用Kaplan-Meier法进行生存分析。结果:两组患者的性别(P=0.51)、年龄(P=0.91)、体能状况评分(P=0.42)、临床分期(P=0.18)、吸烟史(P=0.95)和病理类型(P=0.99)的差异无统计学意义。吉非替尼二线治疗和三线治疗患者的中位无进展生存期分别分别为2.9和3.2个月(P=0.757),有效率分别为17.7%和11.4%(P=0.665),疾病控制率分别为48.4%和54.5%(P=0.822)。吉非替尼二线治疗和三线治疗患者的中位总生存期分别为24.0和21.0个月(P=0.524)。二线治疗获得疾病控制的30例患者以及三线治疗获得疾病控制的24例患者的中位总生存期分别为29.7和22.2个月(P=0.611)。吉非替尼二线治疗与三线治疗的不良反应相似。结论:吉非替尼用于晚期NSCLC二线治疗和三线治疗的缓解率和生存获益无明显差异。

Comparison of therapeutic efficacy of gefitinib as second-and third-line therapies for patients with non-small cell lung cancer

Objective:Gefitinib is generally used in second-or third-line treatment for patients with advanced non-small cell lung cancer(NSCLC).The purpose of this study is to evaluate the prognosis of gefitinib as second-line therapy or third-line therapy in advanced NSCLC.Methods:Medical records and follow-up information of 106 patients with advanced NSCLC were retrospectively reviewed.Sixty-two of 106 were treated with gefitinib as second-line therapy,and 44 were treated with gefitinib as third-line therapy.Surviva...